Atria Wealth Solutions Inc. Acquires 96 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Atria Wealth Solutions Inc. increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.6% during the first quarter, Holdings Channel.com reports. The firm owned 1,812 shares of the medical research company’s stock after buying an additional 96 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in IQVIA were worth $319,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. ING Groep NV lifted its holdings in shares of IQVIA by 72.3% in the 1st quarter. ING Groep NV now owns 24,787 shares of the medical research company’s stock worth $4,370,000 after purchasing an additional 10,400 shares in the last quarter. Smithfield Trust Co lifted its holdings in shares of IQVIA by 112.8% in the 1st quarter. Smithfield Trust Co now owns 583 shares of the medical research company’s stock worth $103,000 after purchasing an additional 309 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of IQVIA by 38.0% in the 1st quarter. Blair William & Co. IL now owns 7,925 shares of the medical research company’s stock worth $1,397,000 after purchasing an additional 2,183 shares in the last quarter. LGT Capital Partners LTD. lifted its holdings in shares of IQVIA by 40.9% in the 1st quarter. LGT Capital Partners LTD. now owns 105,800 shares of the medical research company’s stock worth $18,653,000 after purchasing an additional 30,700 shares in the last quarter. Finally, Malaga Cove Capital LLC lifted its holdings in shares of IQVIA by 52.7% in the 1st quarter. Malaga Cove Capital LLC now owns 3,730 shares of the medical research company’s stock worth $658,000 after purchasing an additional 1,288 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 0.9%

Shares of IQV opened at $191.18 on Friday. The business has a 50-day moving average of $170.40 and a 200 day moving average of $168.83. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The firm has a market cap of $32.50 billion, a P/E ratio of 27.67, a price-to-earnings-growth ratio of 2.08 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same quarter last year, the firm posted $2.64 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on IQV. Barclays increased their target price on IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 23rd. Cowen reissued a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. HSBC lowered IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Redburn Partners set a $188.00 price target on IQVIA in a research report on Friday, May 23rd. Seven equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $228.62.

Insider Activity

In related news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.